Map Key
Generic Enzyme
Generic kinase
Protein kinase
Lipid kinase
Generic phosphatase
Protein phosphatase
Lipid phosphatase
Generic phospholipase
Generic protease
Metalloprotease
G-alpha
RAS - superfamily
G beta/gamma
Regulators (GDI, GAP, GEF)
Generic channel
Ligand-gated channel
Voltage-gated channel
Transporter
Normal process
Pathological process
Positive effect
Negative effect
Unspecified effect
Technical link
Disrupts in disease
Emerges in disease
Enhances in disease
Weakens in disease
Organsim specific interaction

Generic binding protein
Receptor ligand
Cell membrane glycoprotein
Transcription factor
DNA
RNA
Compound
Inorganic ion
Predicted metabolite or user's structure
Reaction
Generic receptor
GPCR
Receptors with enzyme activity
Mitochondria
EPR
Golgi
Nucleus
Lysosome
Peroxisome
Cytoplasm
Extracellular

Normal process
Pathological process
Binding
Cleavage
Covalent modifications
Phosphorylation
Dephosphorylation
Transformation
Transport
Catalysis
Transcription regulation
MicroRNA binding
Competition
Influence on expression
Unspecified interactions
Pharmacological effect
Toxic effect
Group relation
Complex subunit
Similarity reaction
A complex or a group
Organism specific object

Immune response IL-22 signaling pathway


Log In to Post A Comment

Immune response IL-22 signaling pathway

IL-22 signaling pathway

Interleukin-22 ( IL-22 ) is a member of the IL-10 family of cytokines. Themajor sources of IL-22 are activated T cells, especially upon type 1 polarization,and natural killer (NK) cells [1], [2].

IL-22 acts via a heterodimeric receptor complex ( IL-22 receptor )consisting of Interleukin 22 receptor, alpha 1 subunit ( IL22RA1 ) and Interleukin10 receptor, beta subunit ( IL10RB ). Neither resting, nor activated immune cellsexpress IL22RA1, or respond to IL-22. In contrast, tissue cells at outerbody barriers, i.e., of the skin, kidney, and the digestive and respiratory systems aretargets of this cytokine. IL-22 produced by immune cells regulates tissueprotection and homeostasis by promoting the anti-microbial defense, protecting againstdamage, and reorganizing non-immune tissues [3], [4].

In addition to the cell surface associated IL-22 receptor complex, there is asecreted ('soluble'), single-chain Interleukin 22 receptor, alpha 2 ( IL-22RA2 ).IL-22RA2 prevents binding of IL-22 to the functional cell surface IL-22receptor and neutralizes IL-22 activity. IL-22RA2 also blocks inductionof the Suppressor of cytokine signaling-3 ( SOCS3 ) gene expression byIL-22 [4].

IL-22 is expressed in T cells activated by either T cell receptor ( TCRalpha/beta ) stimulation in response to antigen presentation by Majorhistocompatibility complex, class II ( MHC class II ), or stimulation with othercytokines, e.g., Interleukin-9 (IL-9) [5], [2], [4]. IL-22 expression is markedly enhanced in Th1 polarized populations of Tcells rather than Th2 CD4 cells [2]. IL-22 is also expressed by Th17cells, a distinct lineage of effector CD4+ T cells characterized by their production ofInterleukin-17 (IL-17). IL-22 synergizes with IL-17 to regulate genes associatedwith skin innate immunity [6].

Interleukin-2 ( IL-2 ) and Interleukin-12 ( IL-12 ) secreted by CD4+ Tcells and antigen-presenting cells, respectively, act on NK cells that can produceIL-22 in response to IL-2 and IL-12 [1]. IL-2signaling pathway includes IL-2 receptor/ Janus kinases 1 and 3 ( JAK1 andJAK3 )/ Signal transducers and activators of transcription 5 ( STAT5 )activation. IL-12 signaling pathway involves activation of IL-12 receptor/ Janus kinase 2 and Tyrosine kinase 2 ( JAK2 and Tyk2 )/ Signal transducerand activator of transcription 4 ( STAT4 ) [7], [8],[4].

Although activated CD4+ T cells and NK cells secrete IL-22, this cytokine actsexclusively on certain tissue cells. If the production occurs in the lymph nodes, thecytokine binds to IL-22RA2 constitutively expressed by the lymph nodes andprobably acts as a carrier for IL-22 to transport this cytokine to its targetcells [4].

The IL-22 that is produced in infected tissues mostly acts directly on theadjacent tissue cells. IL-22 binding to IL-22 receptor complex leads to theactivation of the receptor-associated Janus kinases JAK1 and Tyk2,followed by activation of transcription factors STAT3, and often STAT1and/or STAT5. These molecules are then phosphorylated by JAK1 andTyk2 to form homodimers that immigrate into the nucleus to induce the expressionof specific genes and therefore modulate the cell activities [2], [3], [4].

STAT3 induces expression of SOCS3, which can negatively regulateJAK1/ STAT3 signaling [9]. STAT3 also up-regulatesexpression of a variety of anti-apoptotic (e.g., B-cell CLL/lymphoma 2 ( Bcl-2 ),BCL2-like 1 ( Bcl-XL ), Myeloid cell leukemia sequence 1 ( Mcl-1 )) andmitogenic (e.g., v-Myc myelocytomatosis viral oncogene homolog ( c-Myc )) proteins[10].

In addition to JAK/STAT signaling, activation of the three major MAP kinase pathways(Mitogen-activated protein kinases 8-10 ( JNK(MAPK8-10) ), Mitogen-activatedprotein kinases 11-14 ( p38 MAPK ) and Mitogen-activated protein kinases 3 and 1 (ERK1/2 )) is also required for maximum IL-22-induced transactivation ofSTAT3 by yet unknown mechanism, and is possibly required for activation ofActivating protein 1 ( c-Jun/c-Fos ), heterodimeric transcription factorconsisting of Jun oncogene ( c-Jun ) and v-Fos FBJ murine osteosarcoma viraloncogene homolog ( c-Fos ), to elicit expression of proinflammatory cytokines[11], [12], [4].